Date: 2014-05-06
Type of information: Fundraising
Company: Avillion (UK)
Investors: Royalty Pharma (UK)
Amount: undisclosed
Funding type: fundraising
Planned used: Royalty Pharma\'s input will be invaluable as the company seeks to identify and accelerate the development of promising product developmentcandidates, taking them through Phase 3 clinical development to marketing approval, beginning with Pfizer\'s Bosulif® (bosutinib).
Others: * On May 6, 2014, Avillion LLP, a company focused on codevelopment and financing of late-stage pharmaceutical candidates from Phase 3 clinical development through marketing approval, announced that Royalty Pharma has become an investor, joining Abingworth LLP and Clarus Ventures. Royalty Pharma will be represented on the Avillion Board by Jim Reddoch, PhD, Executive Vice President for Research and Investments at Royalty Pharma. Dr. Reddoch has been in biotech investment banking and investments for 18 years.
Therapeutic area:
